APA (7th ed.) Citation

C, P., EL, C., A, K., W, Z., E, D., K, O., . . . JH, S. (2023). Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial. Rheumatology and therapy, 10(6), 1795. https://doi.org/10.1007/s40744-023-00593-7

Chicago Style (17th ed.) Citation

C, Perugino, et al. "Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial." Rheumatology and Therapy 10, no. 6 (2023): 1795. https://doi.org/10.1007/s40744-023-00593-7.

MLA (9th ed.) Citation

C, Perugino, et al. "Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial." Rheumatology and Therapy, vol. 10, no. 6, 2023, p. 1795, https://doi.org/10.1007/s40744-023-00593-7.